Immune-Repertoire Profiles in Autoimmune Neurology

Abstract

Autoimmune neurological disorders encompass a spectrum of conditions wherein the immune system aberrantly targets components of the central or peripheral nervous system. Advances in next-generation sequencing have enabled high-resolution profiling of immune repertoires, particularly T- and B-cell receptor diversity, providing novel insights into disease mechanisms, diagnosis, and therapeutic monitoring. This review synthesizes current evidence on immune-repertoire profiling in autoimmune neurology, highlighting recent discoveries, clinical applications, and future directions.

Introduction

Autoimmune neurology is characterized by dysregulated adaptive immune responses targeting neuronal or glial antigens. These disorders include multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), autoimmune encephalitis, and paraneoplastic neurological syndromes. Traditionally, diagnostics have relied on clinical presentation, neuroimaging, and serological detection of pathogenic autoantibodies. However, the advent of high-throughput sequencing of immunoglobulin (Ig) and T-cell receptor (TCR) repertoires has revolutionized our understanding of immune-mediated mechanisms and holds promise for precision medicine approaches. This review provides a comprehensive overview of immune-repertoire profiles in autoimmune neurology, emphasizing clinical relevance and translational opportunities.

Epidemiology / Disease Burden

Autoimmune neurological diseases impose substantial morbidity and healthcare burden worldwide. MS affects over 2.8 million individuals globally, with rising incidence in diverse populations. NMOSD, once considered rare, is now recognized as a distinct entity, particularly prevalent among non-Caucasian groups. Autoimmune encephalitis, notably anti-NMDA receptor encephalitis, is increasingly diagnosed, especially in younger cohorts. The chronic nature of these diseases, often with relapsing courses, necessitates lifelong management and significantly impacts quality of life. Improved diagnostic and prognostic tools, such as immune-repertoire profiling, are critical to reducing disease burden and optimizing therapeutic outcomes.

Pathophysiology

Central to the pathogenesis of autoimmune neurological disorders is the breakdown of immune tolerance, enabling autoreactive T and B lymphocytes to recognize and attack neural antigens. TCR and Ig repertoire sequencing has elucidated the clonal expansion of pathogenic lymphocytes within the central nervous system (CNS) and peripheral blood. In MS, expanded T-cell clones recognize myelin-derived peptides, while in NMOSD and autoimmune encephalitis, pathogenic autoantibodies are produced by clonally related B cells. Oligoclonal bands in cerebrospinal fluid (CSF) reflect intrathecal Ig synthesis. Profiling of these immune repertoires reveals disease-specific patterns of clonal expansion, somatic hypermutation, and antigen-driven selection, informing both pathophysiology and biomarker discovery.

Risk Factors

Genetic predisposition, environmental exposures, and stochastic immune events contribute to the development of autoimmune neurology. Genome-wide association studies implicate HLA alleles and non-HLA loci in disease susceptibility, often influencing TCR and BCR repertoire diversity. Viral infections, such as Epstein-Barr virus, may incite molecular mimicry or bystander activation, altering immune repertoires. Demographic factors (age, sex), vitamin D deficiency, and comorbid autoimmune conditions further modulate risk. Understanding how these factors shape the immune repertoire is essential for unraveling disease etiology and identifying at-risk individuals.

Clinical Features

Autoimmune neurological diseases present with heterogeneous clinical phenotypes, reflecting the diversity of immune targets and pathogenic mechanisms. MS commonly manifests as relapsing-remitting or progressive neurological deficits, with optic neuritis, myelitis, and cerebellar syndromes. NMOSD is characterized by severe optic neuritis and longitudinally extensive transverse myelitis. Autoimmune encephalitis presents with neuropsychiatric symptoms, seizures, and cognitive decline. Paraneoplastic syndromes often exhibit subacute onset and multifocal deficits. Immune-repertoire profiling has the potential to differentiate clinical subtypes, predict disease course, and tailor individualized management strategies.

Diagnosis

Current diagnostic criteria for autoimmune neurological disorders integrate clinical, radiological, and laboratory parameters, including the detection of disease-specific autoantibodies. Immune-repertoire analysis augments traditional diagnostics by identifying clonal expansions and antigen-driven lymphocyte populations in blood and CSF. For instance, high-throughput sequencing can detect oligoclonal TCR or BCR signatures in suspected MS or autoimmune encephalitis cases, even when autoantibody panels are negative. Such molecular profiling aids in early diagnosis, disease classification, and monitoring minimal residual disease post-immunotherapy. Ongoing research seeks to validate immune-repertoire biomarkers for routine clinical use.

Treatment & Management

Therapeutic strategies in autoimmune neurology target pathogenic immune cells and mitigate CNS inflammation. First-line treatments include corticosteroids, plasmapheresis, and disease-modifying therapies (DMTs) such as interferon-beta, glatiramer acetate, and monoclonal antibodies (rituximab, ocrelizumab, eculizumab). Immune-repertoire profiling enables assessment of treatment efficacy by tracking the dynamics of autoreactive clones and B-cell repopulation. Personalized immunotherapy, guided by repertoire signatures, may optimize treatment selection and minimize adverse effects. Resistance to therapy often correlates with persistent or re-emergent pathogenic clones, supporting the need for immune monitoring.

Recent Advances / Emerging Therapies

Recent advances in single-cell sequencing and computational analytics allow in-depth characterization of autoreactive lymphocytes, mapping their phenotype, function, and evolution. Chimeric antigen receptor (CAR) T-cell therapies and targeted B-cell depletion represent promising approaches, especially in refractory cases. Immune-repertoire analysis informs the design of neoantigen-based vaccines and tolerogenic therapies aimed at restoring immune homeostasis. Integration of repertoire data with machine learning algorithms predicts disease activity, relapse risk, and therapeutic response. Clinical trials increasingly incorporate immune-repertoire endpoints to validate biomarkers and stratify patient populations.

Guideline Recommendations

International guidelines emphasize the importance of early recognition and accurate diagnosis of autoimmune neurological disorders, advocating for the integration of novel molecular biomarkers into clinical pathways. The use of immune-repertoire profiling is recommended in research settings and select clinical scenarios, such as atypical presentations or ambiguous serology. Expert consensus supports the development of standardized protocols for repertoire sequencing, data interpretation, and reporting, facilitating multi-center studies and translational application. Ongoing guideline updates will likely incorporate repertoire-based diagnostics as evidence accumulates.

Conclusion

Immune-repertoire profiling represents a paradigm shift in the understanding and management of autoimmune neurological diseases. By delineating disease-specific patterns of lymphocyte clonal expansion and immune dysregulation, repertoire analysis enhances diagnostic accuracy, enables personalized therapy, and informs novel therapeutic strategies. Continued integration of high-throughput sequencing technologies, bioinformatics, and clinical expertise will drive progress toward precision neurology. Future research should focus on large-scale validation of repertoire biomarkers, harmonization of analytic methods, and translation into routine clinical practice to improve outcomes for patients with autoimmune neurological disorders.